What is your approach to the management of patients with isolated cervical adenopathy related to sarcoidosis?
Establishing a diagnosis of sarcoidosis solely on the basis of isolated cervical adenopathy can present a challenge. Although thoracic adenopathy—alone or in combination with other extra-nodal clinical features—is part of the classic illness script for sarcoidosis, peripheral adenopathy as the exclusive manifestation of sarcoidosis is relatively uncommon. The investigators in ACCESS—the largest, multicenter phenotypic cohort study of sarcoidosis conducted to date—identified 2 patients with isolated peripheral adenopathy out of a sample of 736 individuals with biopsy-proven disease (Baughman et al., PMID 11734441). While sampling bias in this population may underestimate the true prevalence of this manifestation, other cohort studies support the epidemiologic rarity of isolated peripheral adenopathy in sarcoidosis (Rizzato and Montemurro, PMID 10746264, 1).
Sarcoidosis is, in part, a diagnosis of exclusion, and it is worthwhile noting that the differential diagnosis for cervical adenopathy is broad and must be thoroughly investigated. Infectious adenitis (due to localized head and neck infection or to systemic infection with such pathogens as mycobacteria, EBV, CMV and toxoplasmosis), lymphoproliferative disorders, solid organ malignancies, and systemic inflammatory diseases including systemic lupus erythematosus, IgG4-related disease or Kikuchi disease can all present with cervical adenopathy.
Once other disorders have been excluded and the diagnosis of sarcoidosis has been established, we can turn our attention to a discussion of management options. Familiarity with the cervical lymph node chain and its relation to the adjacent soft tissue and neurovascular anatomy of the neck is helpful to consider, as symptoms are usually the result of the mass effect on neighboring structures.
As with other non-organ threatening disease manifestations of sarcoidosis, the approach to adenopathy depends on a variety of factors such as symptoms, compromise to surrounding structures, patient preference, and the impact on quality of life. Isolated adenopathy per se need not be treated if nearby structures are unthreatened and the patient is asymptomatic. In that case, the patient can be monitored on a regular basis (initially every 3 to 6 months) to ensure that the bulk and burden of adenopathy is not worsening.
When warranted, treatment typically starts with systemic corticosteroids, with dosing adjusted based on the severity of the complication and urgency of clinical response. Dysphagia due to extrinsic compression of the esophagus may initially require only moderate dosages of corticosteroids (e.g., prednisone 20-30 mg daily), while airway compromise or laryngeal nerve palsy due to bulky disease may require higher dosages (e.g., prednisone 40-60 mg daily). Only rarely are intravenous pulse dose corticosteroids (e.g., methylprednisolone 500-1000 mg daily for 3 days) required to obtain immediate regression of lymphadenopathy, reserved for the most emergent or critical cases.
While corticosteroids are an important tool for gaining rapid control of inflammation, owing to their innumerable unfavorable side effects (hence, our “best worst drug”), we generally abide by the maxim, “the lowest dose needed for the shortest amount of time.” Consequently, we advocate early consideration for the use of steroid-sparing agents, particularly in severe or recurrent cases of lymphadenopathy where long-term immunomodulation is warranted or anticipated. As there are no evidence-based treatment guidelines for the management of isolated cervical adenopathy due to sarcoidosis, empiric treatment options, and clinical practice are extrapolated from the broader experience in sarcoidosis generally, as well as other inflammatory diseases. Nonetheless, reduction of cumulative corticosteroid requirements is an important part of overall management.
Hydroxychloroquine is our first-line steroid-sparing agent of choice because of its relative safety and tolerability, as it is immunomodulatory but not immunosuppressive and is not associated with an increased risk of infections. Alternative but more aggressive options include conventional synthetic immunosuppressive agents such as azathioprine, mycophenolate, and methotrexate. These medications are more consistently effective than hydroxychloroquine but do carry the risk for infectious complications. Anti-TNF-alpha monoclonal antibodies are clearly effective in inducing regression of granulomas and lymphadenopathy but are expensive and also carry a higher risk for infection (Judson, PMID 35838355). JAK inhibitors are an exciting new class of medications that have been nicely demonstrated to reduce lymphadenopathy (Damsky et al., PMID 35668129), but their role remains to be determined.
- Scadding JG, Mitchell DN. Superficial lymphadenopathy. Sarcoidosis. Boston, MA: Springer US; 1985. p. 252-9.
These answers were jointly drafted with Dr. @Dr. First Last.